VEMY vs. BBC

Last updated Aug 4, 2026

VEMY (Virtus Stone Harbor Emerging Markets High Yield Bond ETF) and BBC (Virtus LifeSci Biotech Clinical Trials ETF) are both exchange-traded funds - VEMY is a Emerging Markets Bonds fund actively managed by Virtus, while BBC is a Health & Biotech Equities fund tracking the LifeSci Biotechnology Clinical Trials Index. VEMY is actively managed, while BBC is passively managed. Over the past 3 years, VEMY returned 14.01%/yr vs 29.78%/yr for BBC. Their 0.37 correlation means their historical movements had little consistent relationship. VEMY charges 0.58%/yr vs 0.79%/yr for BBC.

Performance

VEMY vs. BBC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus Stone Harbor Emerging Markets High Yield Bond ETF (VEMY) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, VEMY achieves a 6.07% return, which is significantly lower than BBC's 27.03% return.

VEMY

• 1D: 0.40%
• 1M: -0.46%
• 6M: 3.41%
• YTD: 6.07%
• 1Y: 13.28%
• 3Y*: 14.01%
• 5Y*: —
• 10Y*: —
• ALL TIME*: 13.11%

BBC

• 1D: 0.50%
• 1M: -7.22%
• 6M: 16.85%
• YTD: 27.03%
• 1Y: 132.20%
• 3Y*: 29.78%
• 5Y*: 2.55%
• 10Y*: 9.38%
• ALL TIME*: 6.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
BBC Virtus LifeSci Biotech Clinical Trials ETF	$614.18K	$1.46M	$1.24M
VEMY Virtus Stone Harbor Emerging Markets High Yield Bond ETF	$924.57K	$860.95K	$887.68K

VEMY vs. BBC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
VEMY Virtus Stone Harbor Emerging Markets High Yield Bond ETF	6.07%	15.27%	13.48%	14.45%	-1.43%
BBC Virtus LifeSci Biotech Clinical Trials ETF	27.03%	63.77%	-1.11%	-1.80%	2.46%

Correlation

The correlation between VEMY and BBC is 0.35, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.35
Correlation (3Y) Balances recent behavior with more history.	0.38
Correlation (All Time) Calculated using the full available price history since Dec 13, 2022	0.37

Return for Risk

VEMY vs. BBC — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

VEMY

VEMY Risk / Return Rank: 89
VEMY Sharpe Ratio Rank: 88
VEMY Sortino Ratio Rank: 92
VEMY Omega Ratio Rank: 91
VEMY Calmar Ratio Rank: 85
VEMY Martin Ratio Rank: 91

BBC

BBC Risk / Return Rank: 96
BBC Sharpe Ratio Rank: 97
BBC Sortino Ratio Rank: 95
BBC Omega Ratio Rank: 93
BBC Calmar Ratio Rank: 98
BBC Martin Ratio Rank: 96

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

VEMY vs. BBC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus Stone Harbor Emerging Markets High Yield Bond ETF (VEMY) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	VEMY	BBC	Difference
Sharpe ratio: Return per unit of total volatility	2.21	3.65	-1.44
Sortino ratio: Return per unit of downside risk	3.41	4.08	-0.67
Omega ratio: Gain probability vs. loss probability	1.44	1.48	-0.04
Calmar ratio: Return relative to maximum drawdown	3.33	8.81	-5.48
Martin ratio: Return relative to average drawdown	15.31	23.93	-8.62

VEMY vs. BBC - Sharpe Ratio Comparison

The current VEMY Sharpe Ratio is 2.21, which is lower than the BBC Sharpe Ratio of 3.65. The chart below compares the historical Sharpe Ratios of VEMY and BBC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

VEMY vs. BBC - Drawdown Comparison

The maximum VEMY drawdown since its inception was -8.77%, smaller than the maximum BBC drawdown of -76.85%. Use the drawdown chart below to compare losses from any high point for VEMY and BBC.

Drawdown Indicators

	VEMY	BBC	Difference
Max Drawdown Largest peak-to-trough decline	-8.77%	-76.85%	+68.08%
Max Drawdown (1Y) Largest decline over 1 year	-4.00%	-15.10%	+11.10%
Max Drawdown (3Y) Largest decline over 3 years	-6.57%	-54.45%	+47.88%
Max Drawdown (5Y) Largest decline over 5 years	—	-70.92%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-76.85%	—
Current Drawdown Current decline from peak	-0.68%	-18.46%	+17.78%
Average Drawdown Average peak-to-trough decline	-1.27%	-36.87%	+35.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	0.87%	5.55%	-4.68%

Volatility

VEMY vs. BBC - Volatility Comparison

The current volatility for Virtus Stone Harbor Emerging Markets High Yield Bond ETF (VEMY) is 1.19%, while Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a volatility of 10.19%. This indicates that VEMY experiences smaller price fluctuations and is considered to be less risky than BBC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VEMY	BBC	Difference
Volatility (1M) Calculated over the trailing 1-month period	1.19%	10.19%	-9.00%
Volatility (6M) Calculated over the trailing 6-month period	4.54%	26.25%	-21.71%
Volatility (1Y) Calculated over the trailing 1-year period	6.04%	36.52%	-30.48%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	7.52%	39.61%	-32.09%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	7.52%	37.72%	-30.20%

VEMY vs. BBC - Expense Ratio Comparison

VEMY has a 0.58% expense ratio, which is lower than BBC's 0.79% expense ratio.

Dividends

VEMY vs. BBC - Dividend Comparison

VEMY's dividend yield for the trailing twelve months is around 8.09%, more than BBC's 1.34% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBC Virtus LifeSci Biotech Clinical Trials ETF	1.34%	1.70%	1.00%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%	2.09%	0.00%	0.51%
VEMY Virtus Stone Harbor Emerging Markets High Yield Bond ETF	8.09%	8.89%	10.28%	9.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both VEMY and BBC in my portfolio?

VEMY and BBC have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, VEMY or BBC?

BBC has higher volatility (10.19%) compared to VEMY (1.19%). In terms of maximum drawdown, VEMY dropped -8.77% vs BBC's -76.85%.

Which ETF is better, VEMY or BBC?

On 3-year performance, BBC leads with 29.78% vs 14.01% for VEMY. On fees, VEMY is cheaper at 0.58% per year. On volatility, VEMY has been the lower-risk option at 1.19%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, VEMY or BBC?

Over the 3-year period, BBC has performed better with a 29.78% return vs 14.01%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, VEMY or BBC?

VEMY is cheaper with a 0.58% expense ratio, compared with 0.79% for BBC.

Which ETF pays a higher dividend yield, VEMY or BBC?

VEMY has the higher dividend yield at 8.09%, compared with 1.34% for BBC.

What is the main difference between VEMY and BBC?

VEMY is categorized as Emerging Markets Bonds, while BBC is Health & Biotech Equities. Their fees differ too: 0.58% for VEMY and 0.79% for BBC.

Which has better risk-adjusted returns?

BBC currently has the higher Sharpe Ratio (3.65 vs 2.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.